HIM
TRVI icon

Hillsdale Investment Management’s Trevi Therapeutics TRVI Stock Holding History

Hillsdale Investment Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-86,531
Closed -$133K – 628
2022
Q3 		$133K Buy
+86,531
New +$284K 0.01% 404

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Hillsdale Investment Management's TRVI Position: Q4 2022 in Review

Hillsdale Investment Management sold out of Trevi Therapeutics (TRVI) in Q4 2022, closing a stake of 86,531 shares — an estimated $133K sold.

Hillsdale Investment Management first reported a position in TRVI in Q3 2022 and held it in 1 quarter. The position peaked at $133K in Q3 2022. 37 funds tracked by Wall St. Rank hold TRVI as of Q4 2022.

  • Hillsdale Investment Management reported no remaining Trevi Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Hillsdale Investment Management sold 86,531 Trevi Therapeutics shares in Q4 2022, an estimated $133K.
  • Hillsdale Investment Management first reported a position in Trevi Therapeutics in Q3 2022 and held it in 1 quarter.
  • Hillsdale Investment Management's Trevi Therapeutics position peaked at $133K in Q3 2022.
  • 37 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2022.

Based on Hillsdale Investment Management's 13F filing for Q4 2022, filed 13 Feb 2023.